Streetbeat News

Analyst Ratings

OXM

Telsey Advisory Group has maintained a Market Perform rating on Oxford Industries with a price target of $110.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 7:16 pm

CXM

Rosenblatt analyst Catharine Trebnick maintains a Buy rating on Sprinklr (NYSE:CXM) but lowers the price target from $11 to $10.5.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 7:13 pm

CIEN

Rosenblatt analyst Mike Genovese maintains a Neutral rating on Ciena (NYSE:CIEN) but raises the price target from $54 to $60.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 7:11 pm

GIII

Telsey Advisory Group has maintained a Market Perform rating on G-III Apparel Group with a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 7:09 pm

HOTH

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Hoth Therapeutics (NASDAQ:HOTH) and maintained a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 7:06 pm

CHRD

Chord Energy (NASDAQ:CHRD) has received mixed evaluations from 8 analysts over the past three months, with a majority being bullish. The average 12-month price target is $205.88, a decrease from the previous $214.83. The company shows strong revenue growth and net margin but faces challenges with return on equity.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 7:01 pm

CRGY

Crescent Energy (NYSE:CRGY) received mixed analyst ratings, with a decrease in the average 12-month price target from $20.00 to $19.00. Analysts have varied in their ratings, with some raising and others lowering their price targets. The company has shown strong revenue growth but faces challenges with profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 7:01 pm

CRC

Analysts have recently evaluated California Resources (NYSE:CRC), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased slightly to $63.5. Despite positive analyst sentiment, CRC faces financial challenges, including declining revenue and low profitability metrics.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 7:00 pm

ELV

Analysts have mixed opinions on Elevance Health (NYSE:ELV), with a recent decrease in the average 12-month price target by 1.3%. The company faces challenges with a slight revenue decline but maintains strong profitability metrics. Analyst ratings vary from 'Overweight' to 'Neutral', reflecting diverse market sentiments.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 7:00 pm

ZBH

Analysts have recently shared mixed ratings on Zimmer Biomet Holdings (NYSE:ZBH), with a notable decrease in the average 12-month price target by 7.29%. The company's financial metrics show strong net margins but challenges in ROE and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 7:00 pm